Italian sterile drugmaker Facta Farmaceutici slammed in FDA warning letter

Milan-based sterile drugmaker Facta Farmaceutici has had a plant in Italy slammed in an FDA warning letter.

The FDA has caught an Italian drugmaker apparently manipulating testing data as it reported only passing tests even though original reports indicated out-of-specification results for things like particulate in sterile drugs.

The FDA issued a warning letter to Milan-based Facta Farmaceutici for a plant in San Nicolo a Tordino, Teramo. The FDA had inspected the plant in January 2016, but didn't issue its letter until Jan. 13, 2017, which it posted this week.

The agency spanked the plant for storing the original data in an “unofficial” and uncontrolled electronic spreadsheet on a shared computer network drive. An analyst told the FDA inspector that the data was transcribed later to an “official” form. But of course, the FDA wants to know about failed tests to determine if plants are investigating and dealing with the root cause of OSS readings.  

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

On top of that, the FDA said the inspector saw employees shredding records, including HPLC documents and a partially completed OOS form. “Uncontrolled destruction of CGMP records also raises concerns,” about the effectiveness of its the facility's quality unit and the integrity and accuracy of its CGMP records, the FDA said.

Facta Farmaceutici was given a substantial load of homework, including interviewing employees, past and present, about the recorded lapses and providing the FDA with a complete report on how sterile drugs it has shipped to the U.S. may have been affected by the problems uncovered during the inspection.

The FDA questioned another drugmaker recently about employees destroying documents after video footage showed workers shredding what appeared to be manufacturing and packaging documents at 1 a.m., four days before an FDA inspection at an Hetero Labs facility in Jadcherla, India. 

Suggested Articles

Novartis' AveXis will use Catalent for some manufacturing of its newly approved gene therapy Zolgensma and more manufacturing news of note.

Pharmacy chain Rite Aid has partnered with Google to have their drug recycling stations easily searchable on Google Maps. 

Precision BioSciences says it will have a manufacturing facility for its off-the-shelf CAR-T therapies up and running in the fourth quarter.